GC
ARKG icon

Grimes & Company’s ARK Genomic Revolution ETF ARKG Stock Holding History

Grimes & Company’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,007
Closed -$225K – 301
2021
Q3 		$225K Sell
3,007
-473
-14% -$39.7K 0.01% 272
2021
Q2 		$322K Buy
3,480
+300
+9% +$25.5K 0.01% 235
2021
Q1 		$282K Sell
3,180
-233
-7% -$23.1K 0.01% 234
2020
Q4 		$318K Buy
3,413
+48
+1% +$3.82K 0.02% 213
2020
Q3 		$214K Buy
+3,365
New +$197K 0.01% 233

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Grimes & Company's ARKG Position: Q4 2021 in Review

Grimes & Company sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 3,007 shares — an estimated $225K sold.

Grimes & Company first reported a position in ARKG in Q3 2020 and held it in 5 quarters. The position peaked at $322K in Q2 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Grimes & Company reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Grimes & Company sold 3,007 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $225K.
  • Grimes & Company first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 5 quarters.
  • Grimes & Company's ARK Genomic Revolution ETF position peaked at $322K in Q2 2021.
  • 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Grimes & Company's 13F filing for Q4 2021, filed 1 Feb 2022.